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Summary Combined chemo-/immunotherapy has shown high objective response rates and a significant though small proportion of long-
term complete responders in metastatic malignant melanoma. The purpose of this study was to determine response rates, freedom from
treatment failure (FFTF) and overall survival in patients with advanced metastatic malignant melanoma treated with combined chemo-/
immunotherapy, and to determine the value of a prognostic model for prediction of treatment outcome, FFTF and survival. Sixty-nine patients
with metastatic malignant melanoma received combined chemo-/immunotherapy consisting of up to four cycles of DTIC (220 mg m-2 i.v. days
1-3), cisplatin (35 mg m-2 i.v. days 1-3), BCNU (150 mg m-2 i.v. day 1. cycles 1 and 3 only) and tamoxifen (20 mg orally. daily). Two cycles of
chemotherapy were followed by 6 weeks of outpatient immunotherapy with combined interleukin 2 (20 x 106 U m-2 days 3-5. weeks 1 and 4:
5 x 106 IU m-2 days 1. 3. 5. weeks 2, 3, 5. 6) and interferon-a (6 x 106 IU m-2 s.c. day 1. weeks 1 and 4: days 1. 3. 5. weeks 2, 3. 5. 6). All
patients were evaluated on an intention-to-treat basis. Of 69 patients entered in the study, seven achieved complete remissions and 20
reached partial remissions with an objective response rate of 39% (95% confidence interval 28-52%). Median survival was 11 months.
median FFTF was 5 months. Seven patients achieved ongoing long-term remissions, with maximum survival of 58 + months, and maximum
FFTF of 58 + months. By Kaplan-Meier survival analysis and two-proportional Cox regression analysis, pretreatment performance status and
serum lactic dehydrogenase were statistically significant and independent predictors of survival; risk groups could be defined as (a) the
absence of both or (b) the presence of either one or both of these risk factors. Whereas survival and response were significantly influenced
by patient risk. no infuence could be demonstrated for FFTF. This combined outpatient chemo-/immunotherapy is feasible and results in
objective response rates and survival similar to earlier trials. Pretreatment risk, as defined by serum lactate dehydrogenase (LDH) and
performance status, has a significant impact on treatment outcome and patient survival.
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The incidence ofmalignant melanoma is rising at a rate exceedinct
that of all other tumours (Kirks-%ood et al. 1996). Most patients
present with pigmented skin lesions. and treatment of localized
disease is straightforwsard and surgical. For patients w-ith extensiVe
disease. for example organ metastases. prognosis is poor. Here. the
indication to treat is palliatix e.
Various treatment regimens have been proposed until now. all
with unfasourable results. Chemotherapeutic single-agent regi-
mens give objectixe response rates of up to 20%. with DTIC as
the most effective single agent (McClav and McClav. 1996).
Combination chemotherapx regimens result in objective response
rates as hiah as 55% (DelPrete et al. 1984). However. most of
these regimens have resulted in short survival (McClav and
McClav. 1996l. A further increase in the rate of objectiVe
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responses may be achieved by introducing cxtokines into the ther-
apeutic regimens. with interleukin 2 (IL-2) and interferon alpha
(INF-a) beinc the most widely acclaimed. Monotherapx with IL-2
results in up to 29%c objective responses IRosenberr et al. 1994):
combination regimens sith cvtotoxic drugs reach up to 66%/c
objective response rates depending on the treatment schedule
(Legha. 1997). In a small proportion of patients. long-lasting
remissions can be achieved (Legha. 1997).
The present study shows results of a combined chemo-/
immunotherapx regimen. consisting of three cyvtyotoxic agents
(DTIC. BCNU. cisplatin). tamoxifen and subcutaneous interleukin
2 and interferon alpha. We report objective response rates as sell
as survival. freedom from treatment failure (FF-FT). sites of recur-
rence and prognostic factors for FFTF and survix al.
PATIENTS AND METHODS
Patient characteristics
Betwseen January 1991 and May 1996. 69 patients were entered
into this combined chemo-/immunotherapy protocol. All patients
had histologicall1 confirmed metastatic malignant melanoma. an
1076Metastatic melanoma: treatmentandprognosis 1077
Table 1 Patient characteristics
Characteristic No. of paeits
Entered 69
Sex
Men 45
Women 24
Age (years)
Median 56
Range 20-77
Histology
Nodular 10
Amelanotic 8
Superfical spreading 15
Lentigo maligna 1
Acral lentiginous 5
Unknown 29
Pretreatment
Systemic pretreatment 9
No systemic pretreatment 60
Table 2 Pretreatment nsk factors identified by univariate and multivariate
surval anatysis
Risk factor Categories compared Pvalue
ECOG performnance status < 1 vs. > 1 0.0002*
Serum lactic dehydrogenase s 240 U hi vs. > 240 U ' 0.0011'
Liver mretastases Absent vs. present 0.0048
Brain metastases Absent vs. present 0.0084
Lymphatic metastases Absent vs. present 0.0443
Erythrocyte sedimentation rate < 30 mm1 h vs. > 30 mmi1 h 0.02
'Pretreatment ECOG performance status and serum lactic dehydrogenase
level were rendered statisticalty independent by two-proporbonal Cox
regression analysis.
Table 3 Sites of disease and response to therapy
Site CR PR SD PD Total
Lymphatic 5 12 9 14 40
Visceral 2 9 5 17 33
Pulmonary 3 9 6 12 30
Hepatic 1 9 5 14 29
Cutaneous and 2 3 3 6 14
subcutaneous
Other 1 3 2 7 13
Bone 1 3 2 5 11
Cerebral 0 2 0 3 5
Total (low risk/high risk) 7 (5/2) 20 (13/7) 14 (11/3) 28 (9/19) 69 (38/31)
Shown are absolute numbers of patients; risk groups are defined as absence
of impaired performance status and elevated serum LDH (low risk) or
presence of either one or both ofthese factors (high risk). CR, complete
remission; PR. partial remission; SD. stabilized disease; PR. progressive
disease.
ECOG performance rrade of < 2 and life expectancy > 3 months.
Infonned consent was obtained from each patient before adminis-
tration of any study medication. Important patient characteristics
are listed im Table 1.
Treatment and evaluation
Treatment consisted ofup to four cycles of DTIC (220 mg m-' iV.
days 1-3). cisplatin (35 mg m-' i.v. days 1-3.) BCNIJT (150mg m-
i.v. day 1. cycles 1 and 3 only) and tamoxifen (20 mg orallyv daily).
Two cvcles of chemotherapy were followed by 6 weeks of out-
patient immunotherapy with combined IL-2 (20 x 106 IU m-' s.c.
days 3-5. weeks 1 and 4: 5 x 106 IU m- s.c. days 1. 3. 5. weeks 2
3. 5. 6) and INF-ax2a (6 x 106 lIT m-' s.c. dav 1. weeks 1 and 4:
davs 1. 3. 5. weeks 2. 3. 5. 6). Therapy was administered until
progression of disease. grade III or IV toxicitv (WHO), or sched-
uled end ofadministration.
Re-evaluation of patients was performed according to WHO
criteria. Survival and FF-TF were measured from the initiation of
therapy: response duration was measured from documentation of
response to documentation ofprogression. Patients were evaluated
on an intention-to-treat basis.
Statistical analysis
The probabilitv of overall sun ival was plotted over time
according to the method of Kaplan and Meier. Differences
between groups in overall survival were tested with log, rank statis-
tics: variables demonstrating significant impact on survival in this
univariate analysis were tested for statistical independence in a
multivariate analysis using the Cox proportional hazards model
with forward selection of variables.
RESULTS
Risk model
The ability of vanious pretherapeutic clinical factors to predict
clinical outcome as measured by overall survival was assessed by
using univariate Kaplan-Meier sun-ival analysis and log rank
statistics (Table 2). The following factors demonstrated significant
impact on survival: ECOG performance status, serum lactic acid
dehydrogenase (LDH) level, brain metastases. liver metastases.
lymphatic metastases and erythrocyte sedimentation rate. Using
two-dimensional Cox regression analysis. statistical independence
could be shown for serum LDH and performance status only. This
allowed for definition of two risk groups: (a) low risk in patients
without any ofthese factors (n = 38): (b) high risk forpatients with
either one or both of these factors (n = 31). Clinical variables
tested before therapy and rendered statistically insignificant
included: age, sex. time from first diagnosis to first appearance
of metastases. haemoglobin level. C-reactive protein level.
neutrophil count. bone metastases. pulmonary metastases. cuta-
neous or subcutaneous metastases. and visceral metastases.
Patient nsk and treatment response
Table 3 shows sites of disease and response to therapy for the 69
patients entered into the study. Seven patients had a complete
remission. 20 experienced a partial remission: the objective
response rate was 39% (95%c confidence interval. 28-52%7). Seven
objective remissions are ongoing (Table 4). Stabilization ofdisease
occurred in 14 patients. 28 patients continued to progress despite
therapy. Overall objective response rates were 47.3%7 for low-risk
patients (95% confidence interval. 31-64%) and 29%c for high-risk
patients (95% confidence interval. 14-48%). Ofpatients achieving
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Table 4 Characteristcs of patents with ongoing partial or complete tumour regression
Patient age/sex Sites Risk group Remission FFTF (months) Current status
43fF Lymph nodes Low CR 58+ AJive
Skin
Liver
64/F Lymph nodes High CR 47+ Alive
Skin
Visceral
27/F Lymph nodes High CR 39+ Alive
Skin
47/F Lymph nodes Low CR 32+ Alive
58/F Pulmonary Low CR 26+ Alive
61/MF Lymph nodes Low PR 57+ Alive
Pulmonary
Visceral
29/M Pulmonary High PR 42+ Alive
M, male; F, female; CR. complete remission; PR, partial remission. Risk group as measured by pretherapeutic parameters.
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Figure 1 Kaplan-eier plot of overall survival for the 69 patients entered
into the study
complete remissions. five were at low risk and two were at high
risk. In contrast. progressive patients showed a predominance for
the high-risk group. with 19 patients belonging to the high-risk
group and only nine patients being at low risk. Median response
duration was 7+ months (range. 1-55 months) with 27+ months for
complete and 6 months for partial responders. there were no signif-
icant differences between low- and high-risk patients.
In all patients. most common sites of relapse included lymph
nodes (37%). liver (35%) and lun, (22%). Compared with
metastatic sites before therapy (7%). the proportion of patients
with CNS metastases was increased (19%). In contrast. propor-
tions of patients exhibiting progressive lymphatic (minus 20%).
pulmonary (minus 21%) and visceral metastases (minus 32%).
respectively, were reduced after treatment when compared with
initiation oftherapy.
Ofpatients with progressix e cerebral. hepatic and bone disease.
67'k. 59% and 63%. respectively, showed high-risk features.
whereas patients with lymphatic. pulmonarv and cutaneous/subcu-
taneous metastases belonged predominantly to the low-risk group
(60%. 64% and 67% respectively).
,a 0.8-
X0.6- -a
E 0n4- E
0
0.2-
0.0- 0 12
P<0.0005
Risk groups
---Hgh sk
--+High risk-censored
-Low nsk
-+Low nsk-censored
I
7
7 mm
24 36 48
Months from treatment start
60
Figure 2 Overall survival of 69 patients entered into the study was stratified
for risk group as defined by absence of elevated pretreatnent serum Lactic
dehydrogenase or impaired performance status or presence of either one or
both of these risk factors. Kaplan-Meier plot
Patient risk and survival
Median overall sunrival was 11 months. with a range from 1 to
58+ months (Figure 1). Median sunrival for the high-risk patients
was 6 months, as opposed to 15 months in the low-risk group (P <
0.0005. Figure 2). For complete responders. median survival has
not been reached at 39 months. In comparison (P < 0.007). partial
responders and patients in disease stabilization had a median
survival of 13 and 15 months. respectively. as opposed to a median
survival of 6 months in progressive disease patients (P < 0.0001).
Twelve patients remain alive. five with complete remissions. three
with partial remissions, and four patients with transient disease
stabilization. Of those patients alive. three showed high-risk and
nine showed low-risk features at the beginning oftherapy.
Median FFTF was 5 months. with a range from 0 to 58+ months
(Figure 3). Median FFTF for complete and partial responders was
32+ and 8 months respectively (P <0.003). Seven patients continue
to be progression-free. four of whom showed low-risk features at
initiation oftherapy (Table 4). Median FFTF for low- and high-risk
patients showed no statistically significant difference.
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Figure 3 Kaplan-Meier plot of overall FFTF for the 69 patients entered into
the study
DISCUSSION
Treatment of metastatic maligrnant melanoma has always been a
field of particular disappointment. Although the most common
combination chemotherapy regimen yielded response rates of55%7c
(Del Prete et al. 1984). these responses were usually short-lived
with a median FFT.F of 5 months (Delprete et al. 1984: McClay
and McClav. 1996). This led to the introduction of cvtokines into
the chemotherapeutic regimens. resulting in a significant propor-
tion (approximatelv 10%lc) oflong-term responders (Legha. 1997).
The present sequential chemoimmunotherapy regimen showed
an objective response rate of 39% that is comparable to earlier
chemotherapy-cvtokine combination trials yielding response rates
between 33% and 66%7. with 95% confidence inter-vals from 19%
to 81%e (Richards et al. 1992a. 1992b: Atkins et al. 1994:
Atzpodien et al. 1995: Guida et al. 1996: Keilholz et al. 1997:
Legha. 1997: Thompson et al. 1997). Whereas in most other trials
IL-9 has been administered as continuous i.v. infusion in the
hospital setting and with substantial toxicity. we used both IL-'
and INF-a on an outpatient basis and could significantly reduce
overall side-effects. In previous trials. the sequential administra-
tion of chemo-/immunotherapy has demonstrated therapeutic
superiority over other treatment rerimens including those using
concomitant chemo-/immunotherapy (Leaha. 1997).
The present study is among the first to employ a simple prether-
apeutic risk model comprisinc elevated serum LDH and impaired
performance. This has shown substantial influence on patient's
response to therapy: significantly more complete and partial
remissions were seen in the low-risk group when compared with
high-risk patients. Also. analysis of sites of disease progressing
after or during therapy demonstrated the predictiv-e value of our
risk model: high-risk patients were more likely to progress at clin-
ically serious or life-threatening sites. Most importantly. overall
survival was highly risk-dependent in the present cohort of
patients.
Analysis of the correlation between remission and survival
showed highly increased survival in complete responders.
although no significant survival difference between partial respon-
ders and patients in stabilization could be seen: still. survival in
these groups was substantially increased compared with progres-
sive patients.
Whereas our risk model showed substantial influence on a
patient s response and survival. it did not predict FFTF. Except for
10% of patients achieving ongoing tumour remission and lona-
term survival. in the remaining patients survival appeared to be
influenced by a patient s tumour biology rather than by treatment
efficacy. Analysina the overall survival times. it is clear that only a
small subset of patients was likely to benefit. which was compa-
rable to previous reports (Legha. 1997). Recently published
studies have introduced a risk model based on serum LDH and
cross-sectional surface area ofall measurable metastases (Keilholz
et al. 1997): in this risk model. survival difference betw-een risk
groups was only marginal. whereas the proportion of long-term
responders appeared similar to our results.
In the present study. the therapeutic relevance of additional
outpatient interleukin 2 and interferon alpha remained unclear. To
clearly demonstrate the usefulness of immunotherapy. a prospec-
tive randomized trial is necessarv and has been initiated by this
multicentric study group.
The current risk model suggests the possibility of preselecting
patients that are likely to be long-term responders: on this basis. in
future clinical trials. risk-adapted therapeutic strategies will lead to
more aggressive (Probst-Kepper et al. 1997) and potentially cura-
tiv-e therapies for patients who are likely to be long-term respon-
ders. For malignant melanoma patients at high risk. therapeutic
strategies must achieve effective tumour palliation.
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